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• 06/06/20 4.57 ng/ml PSA
• Abnormal 1.64 ng/ml PSA Velocity increase in 1 year
• 07/16/20 Transrectal ultrasound-guided needle biopsy of prostate 
• Gleason score 3+4 = 7, on right lateral base, right lateral mid, 
right medial mid, and right medial apex involving 40% to 60% of 
invasive adenocarcinoma on prostate 
• Perineural invasion present in some biopsy cores
• Gleason score 3+3 = 6, on right lateral apex involving 15% of 
invasive adenocarcinoma on prostate; no perineural invasion 
• Negative remaining 7/12 biopsy cores
• Patient was diagnosed with favorable intermediate-risk prostate 
cancer
• Diagnosed with stage IIB, T1c, N0, M0, Grade group 2, Gleason 
score 3+4 = 7, invasive adenocarcinoma on right side of prostate 
(refer to figures 1 and 2)
• 08/17/20 Bone scan and CT of abdomen and pelvis
• Negative for tumor metastasis 
• 11/30/20 Hypofractionation treatment began 
• Total dose prescribed of 7,000 cGy delivered in 28 fractions (250 
cGy per fraction)
• 01/12/21 Hypofractionation treatment ended
• Patient reported episodes of mild loose stool at times for 2 
weeks, loss of taste, and decrease in appetite 
• 01/23/21 0.46 ng/ml PSA
• PSA level below threshold 
• 02/11/21 Treatment follow-up
• Patient reported nocturia once per night, hot flashes (from 
androgen deprivation therapy); everything else was negative
• 07/25/21 0.49 ng/ml PSA
• PSA level below threshold
• 08/2021 Treatment follow-up 
• Patient reported nocturia; hot flashes have subsided                 
(Delta Medix, 2020)
Patient Demographics & Medical History
• 54-year-old, male patient 
• Presented with voiding complaints including frequency of urination 
and awakening once per night to void
• Family history of prostate cancer: brother diagnosed at age 61 and 
treated with radiation
• PSA levels were monitored
• 03/12/17 2.09 ng/ml PSA
• 04/14/18 2.2 ng/ml PSA
• 04/14/19 2.93 ng/ml PSA                               (Delta Medix, 2020)
Prostate Cancer Staging 
Conclusion
This research-based project was done to demonstrate the efficacy of a 
moderate hypofractionated regimen for the treatment of favorable 
intermediate-risk prostate cancer. This 54-year-old male patient was 
prescribed a total dose of 7,000 centigrays to be delivered in 28 
fractions (250 centigrays per fraction). He received a total dose of 
7,000 centigrays as prescribed over 43 elapsed days. After completion 
of the treatment, he reported episodes of mild loose stool at times for 
two weeks, loss of taste, and decrease in appetite. One month later he 
reported nocturia once per night and hot flashes. Six months later he 
reported nocturia but no more hot flashes. His PSA was 4.57 ng/ml on 
06/06/20 prior to the start of treatment. Upon treatment completion, his 
PSA was measured to be 0.46 ng/ml on 01/23/21 and 0.49 ng/ml on 
07/25/21. The PSA level decreases demonstrate the efficacy of the 
hypofractionated regimen for the treatment of favorable intermediate-
risk prostate cancer. This regimen shows no overall difference in 
severe gastrointestinal and genitourinary toxicity and reduces the 
overall treatment time, the number of hospital trips, and use of the 
linear accelerator, thus benefitting patients as well as treatment centers. 
Introduction
This research-based project will demonstrate the efficacy of a moderate 
hypofractionated regimen for the treatment of favorable intermediate-
risk prostate cancer. Prostate cancer is a major cause of disease and 
mortality among men. Research indicates that each year, 1.6 million 
men are diagnosed with it and 366,000 die from it. Diagnosis is based 
on rectal examination, serum prostate specific antigen (PSA) 
measurement, and when essential, transrectal prostate needle biopsy 
followed by a Gleason score obtained from it. When treating prostate 
cancer, identifying a Gleason score is the deciding factor in choosing 
from a wide spectrum of treatment options ranging from supervision to 
multimodal treatment. Upon completion of essential tests, the primary 
tumor is assigned a stage based on the American Joint Committee on 
Cancer’s (AJCC) 8th edition Tumor Node Metastasis (TNM) staging 
system for prostate cancer and the patient is placed in a risk group. If 
radiation therapy treatment is required, the patient will undergo a 
process consisting of a treatment simulation followed by treatment 
planning. The preferred External Beam Radiation Therapy (EBRT) 
regimen is moderate hypofractionation. This prospect focuses on a case 
study of a 54-year-old gentleman who successfully underwent pelvic 
radiation therapy using hypofractionation doses for the treatment of 
prostate cancer. 
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Prostate Cancer
• Is unregulated, uncontrolled replication of cells in the prostate 
(Long, Rollins, & Smith, 2019)
• Is the most diagnosed cancer in men with approximately 1.6 million 
incident cases in 2015 (Pernar, Ebot, Wilson, & Mucci, 2018)
• Is the second most common cause of cancer death among men in the 
United States (Pernar et al., 2018)
• Is rare among men younger than forty years of age, with incidence 
rates increasing after age fifty-five (Pernar et al., 2018)
• Is responsible for the diagnosis of 191,930 men in the United States 
in 2020 (Siegel, Miller, & Jemal, 2020)
• Is diagnosed on average at age sixty-six years (Pernar et al., 2018)
Diagnosing Prostate Cancer
• Physical examination by physician 
• Digital rectal examination (DRE)
• Serum prostate specific antigen (PSA) measurement
• Threshold should be less than 4.0 ng/dl (Vane, 2019)
• Velocity increases correlate with risk, aggressiveness, and can 
indicate presence of prostate cancer (Catalona, 2018)
• Transrectal ultrasound-guided prostate needle biopsy
• Provides information about tumor pathology (Öztürk & 
Yıkılmaz, 2018)
• Gleason score 
• First and second most common glandular patterns identified 
(Öztürk & Yıkılmaz, 2018)
• Important in terms of disease course and treatment planning 
(Öztürk & Yıkılmaz, 2018)
• Pathological scores range from 2 to 10 
Hypofractionation Radiation Therapy Facts
• Fraction size between 240 centigrays and 340 centigrays (eviCore
healthcare, 2021)
• Regimens of 6000 centigrays in 20 radiation treatment fractions and 
7000 centigrays in 28 radiation treatment fractions suggested 
(eviCore healthcare, 2021)
• Increases tumor cell killing without causing a corresponding 
increase in damage to surrounding healthy tissues (Campos et al., 
2021)
• Reduces overall treatment time, number of hospital trips, and use of 
linear accelerator, thus benefitting patients and treatment centers 
(Campos et al., 2021)
• Advantageous for radiation therapy treatment centers with limited 
resources, long waiting lists, and/or a geographically dispersed 
population in which many patients live far from the center (Campos 
et al., 2021)
• No overall difference in severe gastrointestinal and genitourinary 
toxicity between non-hypofractionated and hypofractionated 
regimens (Sujenthiran et al., 2020)
Clinical/Pathologic Features: 
Intermediate Risk Group
• Refer to figure 2
• No very high/high-risk group features 
• Grade group 2 or 3 
• Gleason score of 7 (3+4) or (4+3) 
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Figure 2
Risk Factors
• Men between ages of 75 to 84 years have the highest rate of 
mortality (Vane, 2019)
• Men with diagnosed paternal relatives are at two-fold to three-fold 
higher risk of being positive (Pernar et al., 2018)
• Men with paternal relatives who died of prostate cancer have two-
fold higher risk of death compared with men without a family 
history (Pernar et al., 2018)
• Modifiable risk factors 
• Alcohol use (Vane, 2019)
• Obesity (Vane, 2019)
• Cigarette smoking (Vane, 2019)
• High-fat diet (Vane, 2019)
Intermediate Risk Group
• Does not require treatment of pelvic lymph nodes (eviCore
healthcare, 2021)




• Unfavorable intermediate 
Favorable intermediate 
• Grade group 1 or 2
• <50% biopsy cores positive (eg, <6 of 12 cores)
• Prophylactic lymph node radiation and ADT or antiandrogen 
therapy is not used routinely
• Reasonable if additional risk assessments suggest aggressive 
tumor behavior 
• Preferred Hypofractionated dose regiments that have shown 
acceptable efficacy and toxicity
• 3 Gray x 20 fractions
• 2.7 Gray x 26 fractions
• 2.5 Gray x 28 fractions       (Schaeffer et al., 2021)                       
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Varian TrueBeam Linear Accelerator
Gantry 
• Rotates around patient
Cone-beam CT scanner 
• Assesses/verifies patient positioning 
Pillow 
• For patient’s head
Vac-Lok
• Immobilizes lower extremities
Ring
• Immobilizes upper extremities
Pendant 
• Manipulates TrueBeam and table
• Treatment setup is simulated by positioning the patient on the flat 
couch going into the unit headfirst, holding onto ring
• A Vac-Lok immobilization device that minimizes patient movement is 
made simultaneously 
• The patient is aligned to the lasers in the room and marked on the skin 
with tattoos 
• A CT scan will be done to guide the linear accelerator to target the 
lesions accurately and spare critical organs as much as possible during 
treatment 
CT Scanner
• Aligns target for treatment
Pillow
• For patient’s head
Vac-Lok
• Immobilizes lower extremities
Ring
• Immobilizes upper extremities
The TNM System
Tumor
T1: Clinically inapparent tumor that is not palpable
T2: Palpable tumor confined within prostate 
T3: Extraprostatic tumor that does not invade/unfixed 
T4: Tumor is fixed/invades structures other than seminal vesicles 
Node 
NX: Regional lymph nodes cannot be assessed
N0: No positive regional nodes
N1: Metastases in regional node(s)
Metastasis
M0: No distant metastasis
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